Ferrara, Fortunato http://orcid.org/0000-0002-4615-035X
Erasmus, M. Frank
D’Angelo, Sara
Leal-Lopes, Camila
Teixeira, André A.
Choudhary, Alok http://orcid.org/0000-0002-2933-9812
Honnen, William
Calianese, David http://orcid.org/0000-0002-2809-3275
Huang, Deli
Peng, Linghan
Voss, James E.
Nemazee, David
Burton, Dennis R.
Pinter, Abraham
Bradbury, Andrew R. M. http://orcid.org/0000-0002-5567-8172
Funding for this research was provided by:
U.S. Department of Health and Human Services (R01-AI-113266)
Article History
Received: 14 April 2021
Accepted: 14 December 2021
First Online: 24 January 2022
Change Date: 12 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-022-29876-3
Competing interests
: Fortunato Ferrara, M. Frank Erasmus, Sara D’Angelo and Andrew R.M. Bradbury are employees and stockholders of Specifica Inc. All other authors declare no competing interests. The library format described in this paper is covered by the following patent and patent applications, with Specifica always as patent applicant and Andrew R.M. Bradbury, M. Frank Erasmus and André A. Teixeira as inventors: 10,954,508 application status: granted; 17/208,877 application status: allowed; 17/163,170 application status: pending; number EP 19834483.0; application status: pending; Number JP 2021-523556; application status: pending; Number CA 3106115 application status: pending. The antibodies described in the manuscript are covered by the following patent application: patent applicant: Specifica Inc, inventor names: Andrew Bradbury, Fortunato Ferrara, M. Frank Erasmus, number 63/211432, application status: provisional.